CSF Biomarker May Support Lewy Body Diagnosis - Takeaway - MDSpire
From the Journals

CSF Biomarker May Support Lewy Body Diagnosis

A multicohort analysis suggests cerebrospinal fluid DOPA decarboxylase may help distinguish dementia with Lewy bodies and Parkinson’s disease from Alzheimer’s disease and controls

Share

  • 1

    Elevated CSF DDC levels support diagnosis of Lewy body disorders.

  • 2

    Higher DDC concentrations distinguish these disorders from Alzheimer’s disease.

  • 3

    Plasma DDC showed no diagnostic value.

  • 4

    DDC levels correlate with visual hallucinations and parkinsonian symptoms.

  • 5

    Higher CSF DDC is linked to increased alpha-synuclein burden.

  • 6

    Further studies are required across diverse patient populations.

  • 7

    DDC is crucial in dopamine synthesis but the mechanism remains unclear.

Original Source(s)

CSF Biomarker May Support Lewy Body Diagnosis

  • by Henry Thomas

  • April 3, 2026

Related Content

SGLT2 Inhibitors Linked to Lower Epilepsy Risk

Real-world cohort data show lower epilepsy risk vs DPP-4 inhibitors in older patients with type 2 diabetes

Hospital-Treated Infections Linked to Dementia Risk

Investigators identify 29 conditions associated with dementia risk in nationwide registry analysis.

Alzheimer’s Drug Lecanemab Works by “Switching On” the Brain’s Cleanup Cells

Study reveals Fc fragment of antibody is essential for activating microglia to clear amyloid plaques

  • April 7, 2026

  • 3 min